TITLE

Efficacy and safety of lubiprostone in patients with chronic constipation

AUTHOR(S)
Barish, Charles F.; Drossman, Douglas; Johanson, John F.; Ueno, Ryuji
PUB. DATE
April 2010
SOURCE
Digestive Diseases & Sciences;Apr2010, Vol. 55 Issue 4, p1090
SOURCE TYPE
Academic Journal
DOC. TYPE
journal article
ABSTRACT
Aims: The aim of this study is to assess the efficacy and safety of lubiprostone in adults with chronic constipation.Methods: This multicenter, parallel-group trial enrolled 237 patients with chronic constipation and randomized them to 4 weeks of double-blind treatment with oral lubiprostone 24 mcg or placebo twice daily. The primary efficacy endpoint was the number of spontaneous bowel movements (SBMs) after 1 week of treatment. Secondary evaluations included SBMs at weeks 2, 3, and 4; percentage of patients with a SBM within 24 h of first study dose; stool consistency; degree of straining; constipation severity; abdominal bloating and discomfort; global treatment effectiveness; and safety assessments.Results: Lubiprostone-treated patients experienced greater mean numbers of SBMs at week 1 compared with placebo (5.89 versus 3.99, P = 0.0001), with significantly greater percentages having SBMs within 24 h of the first dose (61.3% versus 31.4%, P < 0.0001). At each assessment, SBM frequency and percentages of full responders (> or =4 SBM per week) were significantly greater among lubiprostone-treated patients compared with placebo (P < or = 0.0171). Lubiprostone-treated patients reported significant improvements in stool consistency, straining, and constipation severity at all weeks, and in abdominal bloating at week 1. Patient assessments of treatment effectiveness were significantly greater with lubiprostone compared with placebo at all weeks (P < 0.0004). Gastrointestinal-related disorders were the most common adverse events in both treatment groups.Conclusions: In patients with chronic constipation, lubiprostone produced a bowel movement in the majority of individuals within 24 h of initial dosing, with sustained improvement in frequency as well as other constipation symptoms over 4 weeks of treatment.
ACCESSION #
48600609

 

Related Articles

  • Lubiprostone. McKeage, Kate; Plosker, Greg L.; Siddiqui, M. Asif A. // Drugs;2006, Vol. 66 Issue 6, p873 

    â–´ Lubiprostone (Amitiza) is an oral bicyclic fatty acid that selectively activates type 2 chloride channels in the apical membrane of the gastrointestinal epithelium, resulting in increased fluid secretion.â–´ In two pivotal, randomised, double-blind, multicentre phase III studies in...

  • Insulin Glulisine: A Viewpoint by George Dailey. Dailey, George // Drugs;2006, Vol. 66 Issue 6, p870 

    â–´ Lubiprostone (Amitiza) is an oral bicyclic fatty acid that selectively activates type 2 chloride channels in the apical membrane of the gastrointestinal epithelium, resulting in increased fluid secretion.â–´ In two pivotal, randomised, double-blind, multicentre phase III studies in...

  • Insulin Glulisine: A Viewpoint by Mandana Ahmadian and William C. Duckworth. Ahmadian, Mandana; Duckworth, William C // Drugs;2006, Vol. 66 Issue 6, p870 

    â–´ Lubiprostone (Amitiza) is an oral bicyclic fatty acid that selectively activates type 2 chloride channels in the apical membrane of the gastrointestinal epithelium, resulting in increased fluid secretion.â–´ In two pivotal, randomised, double-blind, multicentre phase III studies in...

  • Insulin Glulisine: A Viewpoint by Jürgen Eckel. Eckel, Jürgen // Drugs;2006, Vol. 66 Issue 6, p870 

    â–´ Lubiprostone (Amitiza) is an oral bicyclic fatty acid that selectively activates type 2 chloride channels in the apical membrane of the gastrointestinal epithelium, resulting in increased fluid secretion.â–´ In two pivotal, randomised, double-blind, multicentre phase III studies in...

  • DOXINATE IN THE TREATMENT OF CONSTIPATION. Cass, Leo J.; Frederik, Willem S. // American Journal of Gastroenterology;Dec1956, Vol. 26 Issue 6, p691 

    Presents results of a clinical trial that indicates the use of dioctyl sodium sulfosuccinate in the treatment of certain types of constipation in infants and children, in immobilized patients and in a variety of proctologic conditions. Dependence of the fecal softening action of the drug upon...

  • A Dose-Ranging, Phase II Study of the Efficacy and Safety of Alosetron in Men with Diarrhea-Predominant IBS. Chang, Lin; Ameen, Vanessa Z.; Dukes, George E.; McSorley, David J.; Carter, Eric G.; Mayer, Emeran A. // American Journal of Gastroenterology;Jan2005, Vol. 100 Issue 1, p115 

    BACKGROUND: A randomized, double blind, placebo-controlled dose-ranging study was conducted to assess the efficacy of alosetron in men with diarrhea-predominant irritable bowel syndrome (IBS).METHODS: Six hundred and sixty-two men were randomized to treatment with alosetron 0.5, 1.0, 2.0, 4.0...

  • Prucalopride for Severe Constipation.  // Clinical Cardiology Alert;Aug2008 Primary Care Supplement, Vol. 13 Issue 8, p16 

    The article discusses research on the use of prucalopride (PRU) against chronic constipation. It references a study by M. Camilleri et al published in a 2008 issue of the "New England Journal of Medicine." According to a double-blind trial of the drug, thirty one percent of patients taking PRU...

  • Polyethylene Glycol for Chronic Constipation. Elliott, William T. // Neurology Alert;Sep2007 Supplement, Vol. 26, p2 

    The article reports on a study from Alabama which found that the long-term use of polyethylene glycol (PEG) is safe and effective for chronic constipation. In the study, more than 300 patients were randomized to receive polyethylene glycol 3350 in a single 17 grams dose per day or placebo for 6...

  • Polyethylene Glycol for Chronic Constipation.  // Clinical Oncology Alert;Sep2007, Vol. 23 Issue 9, p2 

    The article offers information on a study conducted in Alabama that long-term use of polyethylene glycol (PEG) is safe and effective for chronic constipation. It is noted that more than 300 patients were given a single 17g dose of polyethylene glycol 3350 (MiraLAX) per day or placebo for six...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics